<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-920" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Afatinib</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moosavi</surname>
            <given-names>Leila</given-names>
          </name>
          <aff>Kern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Polineni</surname>
            <given-names>Rahul</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leila Moosavi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rahul Polineni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-920.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Afatinib is a tyrosine kinase inhibitor for managing non&#x02013;small cell lung carcinoma (NSCLC). Afatinib&#x000a0;is designed to cause&#x000a0;irreversible inhibition of the ErbB family of tyrosine kinases. The FDA has approved afatinib for treating locally advanced or metastatic NSCLC characterized by nonresistant epidermal growth factor receptor (EGFR) mutations. Additionally, it is a second-line option for advanced squamous NSCLC. Beyond these applications, afatinib is being investigated as a monotherapy for individuals with HER2-positive breast cancer who have experienced progression despite&#x000a0;management with trastuzumab. This activity aims to familiarize healthcare providers with afatinib's approved indications and mechanism of action while addressing potential adverse reactions and highlighting considerations regarding toxicity.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of afatinib.</p></list-item><list-item><p>Determine&#x000a0;the possible adverse effects of afatinib.</p></list-item><list-item><p>Implement&#x000a0;appropriate monitoring for patients&#x000a0;undergoing afatinib therapy.</p></list-item><list-item><p>Develop&#x000a0;interprofessional team strategies for enhancing care coordination and communication to advance afatinib use and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=920&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=920">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-920.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Afatinib is a medication that targets and irreversibly inhibits the ErbB family of tyrosine kinases.<xref ref-type="bibr" rid="article-920.r1">[1]</xref> This drug is FDA-approved for managing locally advanced or metastatic non-small cell lung cancer (NSCLC) associated with nonresistant epidermal growth factor receptor (EGFR) mutations.&#x000a0;Additionally, afatinib is a&#x000a0;second-line treatment of advanced squamous non-small cell lung cancer (NSCLC).<xref ref-type="bibr" rid="article-920.r1">[1]</xref>&#x000a0;Afatinib is also&#x000a0;being investigated as monotherapy in patients with HER2-positive breast cancer who had progressed despite trastuzumab treatment. However, it does not yet have FDA approval for this indication.<xref ref-type="bibr" rid="article-920.r2">[2]</xref></p>
        <p>There are&#x000a0;3 known tyrosine kinase inhibitors (TKIs)&#x000a0;that are proven effective&#x000a0;in treating advanced non-small-cell lung cancer (NSCLC): gefitinib, erlotinib, and afatinib.<xref ref-type="bibr" rid="article-920.r3">[3]</xref>&#x000a0;Based on the reported data, afatinib is not superior to erlotinib in treating EGFR-mutant NSCLC.<xref ref-type="bibr" rid="article-920.r3">[3]</xref>&#x000a0;However, afatinib was more effective than erlotinib in treating advanced squamous cell carcinoma (as second-line treatment).<xref ref-type="bibr" rid="article-920.r3">[3]</xref></p>
        <p>Aredo J. et al found that afatinib had limited activity in patients with non-small&#x000a0;cell lung cancer previously treated with osimertinib who developed resistance to it because of an acquired EGFR mutation.<xref ref-type="bibr" rid="article-920.r4">[4]</xref></p>
        <p>Li. T. examined afatinib activity on uncommon EGFR mutations (eg, Gly719Xaa, Ser768Ile, and Leu861Gln). Forty-two patients with unusual EGFR mutation received treatment with afatinib for advanced lung adenocarcinoma. The investigators found that afatinib was effective in treating this condition.<xref ref-type="bibr" rid="article-920.r5">[5]</xref></p>
        <p>Xu H et al found that afatinib and anlotinib effectively treat lung adenocarcinoma in patients with the rare mutation p.Asp769Tyr.<xref ref-type="bibr" rid="article-920.r6">[6]</xref></p>
        <p>Saran F. et al conducted a&#x000a0;clinical trial in patients with glioblastoma multiforme to determine the maximum tolerated dose of afatinib in combination with radiotherapy and with or without temozolomide. The maximum tolerated dose of afatinib was 30 mg daily with radiotherapy and temozolomide and 40 mg of afatinib with radiotherapy.<xref ref-type="bibr" rid="article-920.r7">[7]</xref></p>
        <p>Afatinib is being examined for treating HER2-positive gastric cancer.<xref ref-type="bibr" rid="article-920.r8">[8]</xref></p>
      </sec>
      <sec id="article-920.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Similarly to&#x000a0;other protein kinase inhibitors,&#x000a0;afatinib's mechanism of action involves irreversibly inhibiting the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4.<xref ref-type="bibr" rid="article-920.r1">[1]</xref>&#x000a0;EGFR and HER2 are part of the receptor tyrosine kinase family and play significant roles in tumor cell proliferation and vascularization. These receptors are known to exhibit overexpression in many cancer cell types.</p>
        <p>Afatinib loses its activity against T790M EGFR mutations, and osimertinib has a high clinical response rate to this mutation.<xref ref-type="bibr" rid="article-920.r9">[9]</xref></p>
        <p>Afatinib exerts antineoplastic effects in head and neck squamous cell carcinoma (HNSCC) by suppressing mTORC1, which initiates apoptosis of the cancer cells.<xref ref-type="bibr" rid="article-920.r10">[10]</xref> Combining autophagy inhibitors with afatinib could improve the treatment of HNSCC.</p>
        <p>Zhu X. et al conducted a study on afatinib-resistant lung adenocarcinoma cell lines (HCC827 AR). The baculovirus IAP repeat protein 5 (BIRC5) was overexpressed in this cell line and was detected on Western blot analysis. BIRC5 overexpression may confer resistance to afatinib by dysregulation of apoptosis. The BIRC5 inhibitor, YM155, restored afatinib activity against the lung adenocarcinoma cell line.<xref ref-type="bibr" rid="article-920.r11">[11]</xref></p>
        <p>Afatinib helps manage&#x000a0;rare epidermal growth factor receptor (EGFR) mutations. It effectively treats&#x000a0;osimertinib resistance mutations, such as G724S and L718Q/V. Afatinib also effectively treats E709X, E709_T710delinsX, some rare exon 19, and some 20 exon insertional mutations. However, some rare exon 19 and some 20 exon insertional mutations do not respond to afatinib treatment.<xref ref-type="bibr" rid="article-920.r12">[12]</xref></p>
      </sec>
      <sec id="article-920.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Afatinib is an orally administered drug that is only available in tablet form. These tablets can be in 20, 30, or 40 mg doses. An afatinib tablet should be taken on an empty stomach at least 1 hour before or 2 hours after a meal, as absorption decreases with high-fat meals. The tablet should be swallowed whole with at least 8 ounces of water. The tablet should never be crushed or dissolved. This medication should be stored at room temperature (68 &#x000b0;F to 77 &#x000b0;F or 20 &#x000b0;C to 25 &#x000b0;C).</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended dosage is 40 mg tablets daily in a patient with normal creatinine clearance without any significant liver dysfunction until the disease progresses or the patient no longer tolerates it.&#x000a0;Following oral administration, the time to peak plasma concentration (Tmax) is reported to be between 2 and 5 hours.<xref ref-type="bibr" rid="article-920.r13">[13]</xref></p>
        <p>For both non-small cell and squamous non-small cell metastatic cancers, dosing is 40 mg orally once daily, preferably more than an hour before or 2 hours after food intake.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dosage adjustment is necessary for mild-moderate (Child-Pugh A or B) hepatic impairment. For severe (Child-Pugh C) hepatic impairment, the patient should be closely monitored, and the dose should be adjusted if not tolerated.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>The dosage changes for patients with kidney disease are based on creatinine clearance (CrCl):&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>30 to 89 mL/min/1.73 m<sup>2</sup>: no dosage adjustment necessary&#x000a0;</p>
          </list-item>
          <list-item>
            <p>15 to 29 mL/min/1.73 m<sup>2</sup>: 30 mg PO daily&#x000a0;</p>
          </list-item>
          <list-item>
            <p>&#x0003c;15 mL/min/1.73 m<sup>2</sup>: Not studied</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-920.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Based on a study by Keating et al, afatinib has a predictable and manageable side effect profile.<xref ref-type="bibr" rid="article-920.r1">[1]</xref>&#x000a0;However, like other medications, it has a particular adverse event profile.&#x000a0;The most commonly reported adverse events are diarrhea and rash/acne in 88% and 82% of patients, respectively.<xref ref-type="bibr" rid="article-920.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dermatologic:
<list list-type="bullet"><list-item><p>Acneiform eruption (&#x02264;90%)</p></list-item><list-item><p>Skin rash (&#x02264;90%)</p></list-item><list-item><p>Paronychia (11% to 58%)</p></list-item><list-item><p>Xeroderma (31%)</p></list-item><list-item><p>Pruritus (10% to 21%)</p></list-item><list-item><p>Cheilitis (12%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Endocrine &#x00026; metabolic:
<list list-type="bullet"><list-item><p>Decreased serum potassium (11% to 30%)</p></list-item><list-item><p>Weight loss (17%)</p></list-item><list-item><p>Hypokalemia (11%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal:
<list list-type="bullet"><list-item><p>Diarrhea (75% to 96%)</p></list-item><list-item><p>Stomatitis (30% to 71%)</p></list-item><list-item><p>Decreased appetite (25% to 29%)</p></list-item><list-item><p>Nausea (21% to 25%)</p></list-item><list-item><p>Vomiting (13% to 23%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Genitourinary:
<list list-type="bullet"><list-item><p>Cystitis (13%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hematologic &#x00026; oncologic:
<list list-type="bullet"><list-item><p>Abnormal lymphocytes (decreased: 38%; grades 3/4: 9%)</p></list-item><list-item><p>Decreased white blood cell count (12%; grades 3/4: 1%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hepatic:
<list list-type="bullet"><list-item><p>Increased serum ALT (10% to 54%)</p></list-item><list-item><p>Increased serum alkaline phosphatase (34% to 51%)</p></list-item><list-item><p>Increased serum AST (7% to 46%)</p></list-item><list-item><p>Abnormal hepatic function tests (6% to 18%)</p></list-item><list-item><p>Increased serum bilirubin (3% to 16%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Ophthalmic:
<list list-type="bullet"><list-item><p>Conjunctivitis (11%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Renal:
<list list-type="bullet"><list-item><p>Decreased creatinine clearance (49%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Respiratory:
<list list-type="bullet"><list-item><p>Epistaxis (17%)</p></list-item><list-item><p>Rhinorrhea (11%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Miscellaneous:
<list list-type="bullet"><list-item><p>Fever (12%)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The following side effects occurred in up to 10% of patients.</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system:
<list list-type="bullet"><list-item><p>Fatigue (under 2%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Dermatologic:
<list list-type="bullet"><list-item><p>Nail disease (3% to 9%)</p></list-item><list-item><p>Palmar-plantar erythrodysesthesia (2% to 7%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Ophthalmic:
<list list-type="bullet"><list-item><p>Keratitis (&#x02264;2%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Renal:
<list list-type="bullet"><list-item><p>Renal insufficiency (6%)</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Respiratory:
<list list-type="bullet"><list-item><p>Interstitial pulmonary disease (2%) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/34794435">[6]</ext-link></p></list-item><list-item><p>Dyspnea (&#x02264;2%)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Liu X et al reported 2 cases of interstitial pneumonia during afatinib therapy.<xref ref-type="bibr" rid="article-920.r15">[15]</xref> The first case is a 58-year-old man with advanced lung adenocarcinoma. The patient had EGFR mutations, including exon 18 G719X and exon 20 S781I. This patient presented with shortness of breath and fever 68 days after starting afatinib therapy&#x000a0;and received treatment with an empirical antimicrobial and a low-dose glucocorticoid. The afatinib-induced interstitial pneumonia was not diagnosed. The patient died 15 days after the onset of symptoms because of pulmonary inflammation.</p>
        <p>The second case is a 57-year-old man with advanced lung adenocarcinoma. The patient had EGFR mutations, including exon 21 L861Q. This patient presented with shortness of breath and fever 22 days after starting afatinib therapy. The patient received empirical antimicrobial treatment, and&#x000a0;5 days later, the patient received a CT scan, which showed pulmonary inflammation. The patient was diagnosed with afatinib-induced interstitial pneumonia and was promptly treated with glucocorticoid therapy, which quickly resolved the pneumonia. The investigators concluded that clinicians must be vigilant for the uncommon event of afatinib-induced interstitial pneumonia and treat it promptly with glucocorticoid therapy.</p>
      </sec>
      <sec id="article-920.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>No contraindications are listed in the manufacturer's labeling thus far. However, prescribers should withhold dosing for any adverse drug reactions.<xref ref-type="bibr" rid="article-920.r16">[16]</xref></p>
        <p>Permanent discontinuation of this drug is required if any of the following are recorded.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Life-threatening bullous, blistering, or exfoliative skin lesions.</p>
          </list-item>
          <list-item>
            <p>Interstitial lung disease (ILD)</p>
          </list-item>
          <list-item>
            <p>Severe drug-induced hepatic impairment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Persistent ulcerative keratitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Symptomatic left ventricle dysfunction</p>
          </list-item>
          <list-item>
            <p>Severe&#x000a0;or intolerable adverse reactions occurring at a dose of 20 mg/d&#x000a0;</p>
          </list-item>
        </list>
        <p>This drug is not recommended during pregnancy, as no adequate clinical trials exist examining the drug's use during pregnancy. Instead, a strong recommendation is that women of reproductive age use an&#x000a0;effective contraception method during therapy. It should be continued at least 2 weeks after the last dose of afatinib.&#x000a0;The manufacturer warns against using this medication during breastfeeding, given the potentially severe adverse reactions in a breastfed infant.&#x000a0;Breastfeeding can resume&#x000a0;2 weeks after the last dose.<xref ref-type="bibr" rid="article-920.r17">[17]</xref></p>
      </sec>
      <sec id="article-920.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Afatinib has&#x000a0;several monitoring requirements.<xref ref-type="bibr" rid="article-920.r18">[18]</xref><xref ref-type="bibr" rid="article-920.r19">[19]</xref>&#x000a0;These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Since dermatology adverse reactions are the most commonly reported during treatment, patients should be advised to avoid sun exposure if possible or utilize adequate sun protection.<xref ref-type="bibr" rid="article-920.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Monitor for signs and symptoms of volume depletion in patients with diarrhea.</p>
          </list-item>
          <list-item>
            <p>Hepatic impairment was commonly observed in clinical trials; it is advised to monitor liver function periodically during treatment.</p>
          </list-item>
          <list-item>
            <p>Renal function requires periodic monitoring.</p>
          </list-item>
          <list-item>
            <p>Keratitis is one of the rare adverse effects reported in clinical trials; therapy should be interrupted with any suspected keratitis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>It is recommended to reduce the dose in patients with paronychia.</p>
          </list-item>
          <list-item>
            <p>Monitor patients for any signs and symptoms that&#x000a0;raise concern for pulmonary toxicity; interstitial lung disease occurred in a small percentage of patients.</p>
          </list-item>
          <list-item>
            <p>Assess left ventricle function before and during treatment in patients with high-risk cardiac conditions. This drug should be used with caution in patients with cardiac risk factors or decreased left ventricle heart failure, as patients with significant cardiac history met exclusion criteria for clinical trials.</p>
          </list-item>
        </list>
        <p>Takahashi T et al studied using afatinib trough plasma concentrations in patients with non&#x02013;small cell lung cancer to improve the safety and efficacy of afatinib therapy.<xref ref-type="bibr" rid="article-920.r21">[21]</xref></p>
      </sec>
      <sec id="article-920.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Limited research and data regarding&#x000a0;toxic&#x000a0;and therapeutic levels of afatinib are available. However, it has been reported to have&#x000a0;a predictable&#x000a0;and manageable profile in terms of side effects.</p>
        <p>Some severe adverse reactions&#x000a0;have been identified, including hepatic impairment, dermatology complications, and rarely lung and cardiac complications.&#x000a0;Afatinib should be dose-adjusted in case of concomitant treatment with P-glycoprotein inducers or inhibitors.<xref ref-type="bibr" rid="article-920.r13">[13]</xref></p>
      </sec>
      <sec id="article-920.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Afatinib is an orally administered drug for the treatment of&#x000a0;metastatic non-small cell lung cancer, which was FDA-approved in 2013. Although this drug can easily be administered by patients orally as once-daily dosing, close follow-up with the oncologist or primary care clinician, specialty-trained nurses, and pharmacists are necessary during the treatment. Pharmacists&#x000a0;are&#x000a0;the best primary source for patients' questions or concerns. They can also perform medication reconciliation, verify dosing, and should report any issues to the prescribing physician or nurse. Nurses will encounter patients at follow-up visits and document medication&#x000a0;adherence and signs of adverse events, which they should communicate with the rest of the interprofessional healthcare team. All interprofessional team members are responsible for reporting all interactions, observations, test results, and interventions in the patient's medical record; this allows all team members to operate from the same up-to-date information.</p>
        <p>Better communication between health care providers, patients, and pharmacists is recommended to improve patient care and build a better&#x000a0;adverse effect profile, eventually leading to better patient care. This collaboration demonstrates the clinical benefit of an interprofessional healthcare team.</p>
      </sec>
      <sec id="article-920.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=920&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=920">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/920/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=920">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-920.s11">
        <title>References</title>
        <ref id="article-920.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.</article-title>
            <source>Target Oncol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>825</fpage>
            <page-range>825-835</page-range>
            <pub-id pub-id-type="pmid">27873136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Munster</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frakes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Cleator</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uttenreuther-Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wind</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vinisko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hickish</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>1057</fpage>
            <page-range>1057-65</page-range>
            <pub-id pub-id-type="pmid">22418700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hackshaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.</article-title>
            <source>Int J Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>140</volume>
            <issue>12</issue>
            <fpage>2805</fpage>
            <page-range>2805-2819</page-range>
            <pub-id pub-id-type="pmid">28295308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aredo</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Wakelee</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Padda</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.</article-title>
            <source>Cancer Treat Res Commun</source>
            <year>2022</year>
            <volume>30</volume>
            <fpage>100497</fpage>
            <pub-id pub-id-type="pmid">34920242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.</article-title>
            <source>Thorac Cancer</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>21</issue>
            <fpage>2924</fpage>
            <page-range>2924-2932</page-range>
            <pub-id pub-id-type="pmid">34549528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.</article-title>
            <source>World J Surg Oncol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>18</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>330</fpage>
            <pub-id pub-id-type="pmid">34794435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saran</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McBain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gattamaneni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jefferies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pemberton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schaible</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cseh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brada</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.</article-title>
            <source>J Neurooncol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>155</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-317</page-range>
            <pub-id pub-id-type="pmid">34787778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>HER2-targeted therapies in gastric cancer.</article-title>
            <source>Biochim Biophys Acta Rev Cancer</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>1876</volume>
            <issue>1</issue>
            <fpage>188549</fpage>
            <pub-id pub-id-type="pmid">33894300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hochmair</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burghuber</surname>
                <given-names>OC</given-names>
              </name>
              <name>
                <surname>Prosch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hilbe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cseh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Filipits</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.</article-title>
            <source>Target Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-83</page-range>
            <pub-id pub-id-type="pmid">30539501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Suo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Afatinib induces pro-survival autophagy and increases sensitivity to apoptosis in stem-like HNSCC cells.</article-title>
            <source>Cell Death Dis</source>
            <year>2021</year>
            <month>Jul</month>
            <day>22</day>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>728</fpage>
            <pub-id pub-id-type="pmid">34294686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Identification and Validation of Afatinib Potential Drug Resistance Gene <italic>BIRC5</italic> in Non-Small Cell Lung Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>763035</fpage>
            <pub-id pub-id-type="pmid">34804966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.</article-title>
            <source>Curr Oncol</source>
            <year>2023</year>
            <month>May</month>
            <day>28</day>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>5337</fpage>
            <page-range>5337-5349</page-range>
            <pub-id pub-id-type="pmid">37366888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wind</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ebner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freiwald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stopfer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-250</page-range>
            <pub-id pub-id-type="pmid">27470518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niebecker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Staab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freiwald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.</article-title>
            <source>CPT Pharmacometrics Syst Pharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>230</fpage>
            <page-range>230-239</page-range>
            <pub-id pub-id-type="pmid">30681293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>698447</fpage>
            <pub-id pub-id-type="pmid">34721009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masters</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Temin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azzoli</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Giaccone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Gajra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rackear</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Strawn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
              <collab>American Society of Clinical Oncology Clinical Practice</collab>
            </person-group>
            <article-title>Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <day>20</day>
            <volume>33</volume>
            <issue>30</issue>
            <fpage>3488</fpage>
            <page-range>3488-515</page-range>
            <pub-id pub-id-type="pmid">26324367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Afatinib</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">29999905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jobe</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ahonen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Poplin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohyuddin</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Jun</month>
            <day>14</day>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e2805</fpage>
            <pub-id pub-id-type="pmid">30123727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maarof</surname>
                <given-names>NNN</given-names>
              </name>
              <name>
                <surname>Alsalahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdulmalek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fakurazi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tejo</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Abdul Rahman</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Feb</month>
            <day>08</day>
            <volume>13</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33567737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>160</volume>
            <fpage>103305</fpage>
            <pub-id pub-id-type="pmid">33757838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-920.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Terazono</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suetsugu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okutsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>08</day>
            <volume>13</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">34298637</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
